Список литературы

1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011 Feb 10; 29(5): 573 - 82. doi: 10.1200/JCO.2010.29.8711.

2. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных заболеваний Клиническая онкогематология. 2016; 9 (3): 314 - 325.

3. R.C. Skoda, A. Duek, J. Grisouard. Pathogenesis of myeloproliferative neoplasms. Experimental Hematology. Volume 43, Issue 8, August 2015, Pages 599 - 608 https://doi.org/10.1016/j.exphem.2015.06.007

4. Schischlik F., Kralovics R. Mutations in myeloproliferative neoplasms - their significance and clinical use. Expert Rev Hematol. 2017 Nov; 10(11): 961 - 973. doi: 10.1080/17474086.2017.1380515. Epub 2017 Sep 25.

5. W. Vainchenker, Franc,ois Delhommeau, 1, 2, 4 Stefan N. Constantinescu, 5, 6 and Olivier A. Bernard. New mutations and pathogenesis of myeloproliferative neoplasms. BLOOD, 2011. 118(7): 1723 - 1735; doi: https://doi.org/10.1182/blood-2011-02-292102

6. H.C. Hasselbalch, M.E. . MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators Inflamm. 2015; 2015: 102476. doi: 10.1155/2015/102476.

7. Mehta J., Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar; 55(3): 595 - 600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.

8. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. Монография. С-Пет. 2016; 298

9. D.A. Arber, A. Orazi, R. Hasserjian, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia//Blood. - 2016. - Vol. 127, N 20. - P. 2391 - 2405.

10. Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Jean-Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter A.W. te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. J Clin Oncol. 2012; 30(33): 4098 - 4103. doi: 10.1200/JCO.2012.42.3863

11. Vannucchi A.M., T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. , J. Thiele, Buske C. Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms: ESMO Clinical Practice Guidelines Ann Oncol (2015) 26 (suppl 5): v85 - v99.

12. Agarwal M.B., Malhotra H., Chakrabarti P., Varma N., Mathews V., Bhattacharyya J., T. Seth, K. Gayathri, H. Menon, P.G. Subramanian, A. Sharma, M. Bhattacharyya, J. Mehta, A.K. Vaid, S. Shah, S. Aggarwal, P.K. Gogoi, U. Agarwal, Varma. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia Indian J Med Paediatr Oncol. 2015 Jan - Mar; 36(1): 3 - 16. doi: 10.4103/0971-5851.151770

13. Busque L, Porwit A, Day R, Olney HJ, Leber B, V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016 Oct; 146(4): 408 - 22. doi: 10.1093/ajcp/aqw131.

14. Hoffman R. et al. Hematology: Basic Principles and Practice E-Book 7th edition 2017 https://books.google.de/books?isbn=0323509711

15. Toros A.B., Gokcay S., Cetin G., Ar M.C., Karagoz Y., Kesici B. Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed. ISRN Hematol. Volume 2013, Article ID 673781, 5 pages http://dx.doi.org/10.1155/2013/673781

16. Pieri L., Guglielmelli P., Vannucchi A.M. Chronic Myeloproliferative Neoplasms: a Collaborative Approach. Mediterr J Hematol Infect Dis. 2010; 2(2): e2010017. Published online 2010 Jun 21. doi: 10.4084/MJHID.2010.017

17. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23(10): 2224 - 2232

18. Michiels J.J., Berneman Z., Schroyens W. et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32: 589 - 604.

19. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep; 27(9): 1874 - 81. doi: 10.1038/leu.2013.163.

20. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015 Nov 27; 5: e369. doi: 10.1038/bcj.2015.94.

21. Cervantes F. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009. 113(13). 2895 - 901.

22. Passamonti F., Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010; 116(15): 2857 - 8. doi: 10.1182/blood-2010-06-293415.

23. Gangat N., Caramazza D., Vaidya R. et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology. 2011. 29(4). 392 - 7.

24. Vannucchi AM, P. Guglielmelli, Rotunno G, Pascutto C, Pardanani A. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project//Blood. - 2014. - P. 405

25. Tefferi, P. Guglielmelli, C. Finke, et al. Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis//Blood. - 2014. - Vol. 124. - P. 406.

26. Falchi L, Newberry KJ, Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl: S27 - 33. doi: 10.1016/j.clml.2015.02.013.

27. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2013. 88(6); 507 - 516

28. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология 2017; 1: 25 - 60.

29. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European Leukemia Net consensus conference. Blood 2009; 113(20): 4829 - 4833.

30. Fogliatto L., R. Breunig, T.V. Costa, L. Carlos Z. Contin, J.F. Silveira, C. Silveira, L.E. Daudt, L. Silla The Assessment of the European Leukemianet Criteria for Clinicohematologic Resistance and Intolerance to Hydroxyurea in Polycythemia Vera Is Not Easily Applicable in Daily Practice. Blood 2014 124(21): 5550; https://doi.org/

31. Alvarez-Larran A., Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010; 116: 1205 - 10.

32. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev. 2003; 2: 15 - 28

33. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019 Jan; 94(1): 133 - 143. doi: 10.1002/ajh.25303.

34. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 Dec; 93(12): 1551 - 1560. doi: 10.1002/ajh.25230.

35. Shantzer L, Berger K, Pu JJ. Primary myelofibrosis and its targeted therapy. Ann Hematol. 2017 Apr; 96(4): 531 - 535. doi: 10.1007/s00277-016-2785-9.

36. McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019 Apr; 104(4): 659 - 668. doi: 10.3324/haematol.2018.206151.

37. Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, Xhaard A, Sicre de Fontbrune F, Peffault de Latour R, Sarfati E, G. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jun; 23(6): 958 - 964. doi: 10.1016/j.bbmt.2017.03.002.

38. Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ. Benefits and pitfalls of pegylated therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018 Mar; 103(3): 438 - 446. doi: 10.3324/haematol.2017.181297.

39. JC, Correa JG, R, J, A, Fox ML, V, M, F, MI, Raya JM, Estrada N, S, Kerguelen A, MA, Albors M, Cervantes F. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol. 2017 Apr; 98(4): 407 - 414. doi: 10.1111/ejh.12846.

40. Cervantes F., A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005; 129(6): 771 - 5.

41. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein M.N. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000; 95(7): 2226 - 33.

42. Меликян А.Л., Колосова Л.Ю., Соколова М.А., Ковригина А.М., Силаев М.А., Гилязитдинова Е.А., Гемджян Э.Г., Карагюлян С.Р. Роль спленэктомии при лечении больных миелофиброзом. Тер. архив. 2013. 8, 69 - 76.

43. Melikyan A.L., Kovrigina A.M., Sokolova M.A., Kolosova L.U., Silaev M.A., Gilyazitdinova E.A., Subortseva I.N., Gemdjian E.G., Karagulyan S.R, Savchenko V.G. The Role Of Splenectomy In The Treatment Of Myelofibrosis Blood. 2013.

44. Tefferi. How I treat myelofibrosis. BLOOD, 2011; 117(13): 3494 - 3504 doi: 10.1182/blood-2010-11-315614

45. Nicolosi M, Mudireddy M, Patnaik MM, Gangat N, Pardanani A, Tefferi A. A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. Am J Hematol. 2018 Aug; 93(4): E103 - E107. doi: 10.1002/ajh.25037.

46. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P. Iron toxicity - Its effect on the bone marrow. Blood Rev. 2018 Nov; 32(6): 473 - 479. doi: 10.1016/j.blre.2018.04.004.

47. A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 1; 27(28): 4760 - 6. doi: 10.1200/JCO.2009.22.6548.

48. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010 Nov 25; 116(22): 4436 - 8. doi: 10.1182/blood-2010-05-287417.

49. Tefferi, F. Cervantes, R. Mesa, F. Passamonti, S. Verstovsek, A.M. Vannucchi, J. Gotlib, B. Dupriez, Animesh Pardanani, Claire Harrison, Ronald Hoffman, Heinz Gisslinger, Nicolaus , Juergen Thiele, Tiziano Barbui and Giovanni Barosi Revised response criteria for myelofibrosis: International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013 122: 1395 - 1398; doi: https://doi.org/10.1182/blood-2013-03-488098

50. Scherber RM, Mesa RA. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018 Nov 30; 2018(1): 118 - 126. doi: 10.1182/asheducation-2018.1.118.

51. Pedersen KM, Zangger G, Brochmann N, BM, Zwisler AD, Hasselbalch HC, Tang LH. The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms - An explorative study. Eur J Cancer Care (Engl). 2018; 27(5): e12865. doi: 10.1111/ecc.12865.

52. Samuelson, Bethany T.; Vesely, Sara K.; Chai-Adisaksopha, Chatree; Scott, Bart L.; Crowther, Mark; Garcia, David The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagulation & Fibrinolysis: September 2016 - Volume 27 (6) - p 648 - 652 doi: 10.1097/MBC.0000000000000446

53. Шмаков Р.Г., Полушкина Е.С. Особенности репродуктивной функции у женщин с онкогематологическими заболеваниями. Современная онкология. 2008. 10(3). 68 - 69